Favipiravir is primarily used as an antiviral medication, particularly effective against RNA viruses. It has gained significant attention for its application in treating influenza, especially in cases where other antiviral drugs are ineffective. During the COVID-19 pandemic, it was explored as a potential treatment for SARS-CoV-2 infections, with some countries approving its emergency use to reduce viral load and alleviate symptoms. Additionally, it has shown promise in combating other viral infections such as Ebola, Lassa fever, and yellow fever. Its mechanism of action involves inhibiting viral RNA-dependent RNA polymerase, thereby preventing viral replication. Favipiravir is often administered orally, making it convenient for outpatient treatment. However, its use is typically reserved for severe or resistant cases due to potential side effects and the need for further clinical research to fully establish its efficacy and safety profile.